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Abstract
Background: Preeclampsia (PE) is associated with maternal and neonatal morbidity and mortality. In PE, the
physiological hyperlipidaemia of pregnancy is exaggerated. The purpose of this study was to examine the
expression of adipose triglyceride lipase (ATGL), hormone sensitive lipase (HSL), lipoprotein lipase (LPL) and
endothelial lipase (EL) in pregnancies complicated by PE.
Methods: Placentae were collected from 16 women with PE and 20 women with uncomplicated pregnancies
matched for maternal prepregnancy BMI and gestational age of delivery. Gene and protein expression of the
placental lipases were measured by Q-PCR and Western blot. DNA methylation of the promoter of LPL was
assessed by bisulfite sequencing. Lipase localisation and activity were analysed.
Results: Gene expression of all lipases was significantly reduced, as was HSL protein level in women with PE. All
lipases were localised to trophoblasts and endothelial cells in PE and control placentae. There was no difference in
methylation of the LPL promoter between PE and control placentae. Lipase activity was not altered in placentae
from women with PE.
Conclusion: These results suggest that the decreased placental lipase gene but not protein expression or lipase
activity, which is associated with late-onset PE is not a major contributor to the abnormal lipids seen in PE.
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Background
Preeclampsia (PE) occurs in ~ 5 % of pregnancies in the
developed world. During pregnancy, PE is associated
with maternal multiorgan dysfunction, placental abrup-
tion and poor fetal growth. In the longer term, PE pre-
dicts maternal hypertension and carries an increased
maternal cardiovascular and renal morbidity [1, 2]. One
adverse infant outcome associated with PE is intrauter-
ine growth restriction (IUGR), a failure of the infant to
reach its full potential growth [3]. IUGR is associated
with perinatal morbidity and mortality and also with
hypertension and cardiovascular disease later in life for
the infant [4, 5].
In PE, most studies report exaggerated and early ma-
ternal gestational hyperlipidaemia [6–8], with marked
hypertriglyceridemia, higher very low density lipoprotein
(VLDL) concentrations [9] and higher levels of small,
dense low density lipoprotein (LDL) [10]. There is also a
rise in maternal free fatty acid (FFA) concentrations above
normal pregnancy levels [11]. This excessive increase in
maternal lipids is thought to contribute to endothelial dys-
function, one of the hallmarks of PE [12, 13]. PE is also as-
sociated with abnormalities in lipid oxidation, which may
be part of the underlying pathophysiology of the condition
[12, 13]. Women with a history of PE demonstrate persist-
ent abnormalities in lipids postpartum [14, 15].
The placenta supplies fatty acids (FFA) and cholesterol
to the infant. While FFAs can diffuse across the placenta,
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most lipids require active placental transport through
the activity of lipoprotein receptors, lipases and fatty
acid binding proteins [16, 17]. Abnormal maternal lipids
or altered placental lipid processing could contribute to
the altered infant growth and change in cord lipopro-
teins seen in PE. The expression and activity of lipopro-
tein lipase (LPL) has been variably found to be higher,
lower or unchanged in placentae from women with PE
or IUGR compared to uncomplicated pregnancy
[18–26]. Endothelial lipase (EL) gene expression has
been reported to be decreased in IUGR [19] but has not
been analysed in PE. The expression and localization of
the intracellular lipases adipose triglyceride lipase
(ATGL) and hormone sensitive lipase (HSL) have not
previously been examined in placentae from women
with pregnancies complicated by PE or IUGR.
The current study aims to examine placental lipase ex-
pression in late-onset PE. Placental gene, protein expres-
sion and localization of ATGL, HSL, EL and LPL was
analysed in placentae from women with PE and IUGR
and uncomplicated pregnancy. Furthermore, DNA methy-
lation of the promoter of LPL was investigated and overall
lipase activity was examined.
Methods
Subjects
Pregnant women in the third trimester were recruited
from a tertiary general and obstetric hospital. All women
gave written informed consent. Permission for the study
was granted by the Human Research Ethics Committees
of the Royal Brisbane and Women’s Hospital and The
University of Queensland. Diagnosis of PE was defined
by current Society of Obstetric Medicine, Australia New
Zealand guidelines research definition [27]. Participants
were matched for maternal BMI, which was calculated
from a recorded early pregnancy weight in kg divided by
the squared height in meters. The customized birth cen-
tile was calculated with the online calculator gestation.net
(www.gestation.net). Small for gestational age (SGA)
infants were defined as adjusted birth weight centile <
10th. Placental tissue was collected immediately post-
delivery, sampled randomly (~ 1 cm3) but away from
areas of infarction or calcification, snap-frozen in liquid
nitrogen and kept at -800 C until analysis. In addition,
1 cm3 samples of placenta for paraffin embedding were
washed in PBS, placed into 4 % paraformaldehyde for
48 hours and kept in a saturated sucrose solution until
embedding.
Ethics approval
This study was approved by the Human Research Ethics
Committees of the Royal Brisbane and Women’s Hos-
pital (HREC/08/ARBW/16: 19/01/2009) and The Uni-
versity of Queensland (2009000115: 04/02/2009).
RNA isolation and quantitative real-time PCR
Placental tissue was lyzed by violent shaking for 2 × 2
minutes at 30 Hz with a 5 mm stainless steel bead in a
TissueLyser (Qiagen, Chadstone, VIC, Australia). mRNA
was isolated from placenta with the Allprep RNA/DNA
extraction mini kit (Qiagen). RNA was quantified by
Nanodrop and all samples had 260/280 ratios > 1.8.
750 ng mRNA was reverse transcribed to cDNA with
the QuantiTect reverse transcription kit (Qiagen) using
an equal mixture of oligodT and random primers. Quan-
titative real-time PCR was performed on 18.75 ng of
cDNA with 300 nM of primers and iTaq universal SYBR
green mastermix (Bio-Rad, Gladesville, NSW, Australia)
on an iQ5 PCR machine (BioRad). The PCR protocol
consisted of 1 cycle at 95 °C for 10 min, 40 cycles of 95 °
C for 15 sec and 59 °C for 1 min followed by dissoci-
ation curve analysis. Primers unique for the target gene
and covering exon-exon junctions were designed with
primerBLAST. The primer sequences are presented in
Table 1. To adjust for potential differences in cellular
composition of the placental samples, gene expression
was normalized to the geometric mean of expression of
the housekeeping gene TATA-box binding protein
(TBP), cytokeratin 7 (CK7) as a marker for trophoblast
cells, CD34 (CD34) for endothelial cells and desmin
(DES) for smooth muscle cells. The analysis was also
Table 1 Primer sequences





CK7 5′- CCGTGCGCTCTGCCTATGGGG 5′- GCTCCAGAAACCGCACCTTGTCGAT
CD34 5′- CCACAGGAGAAAGGCTGGGCGA 5′- AGCCCCTCGGTTCACACTGGC
DES 5′- TCCGAGAAACCAGCCCTGAGCAA 5′- GTGGCCTCACTGACGACCTCCC
TBP 5′-GGGCACCACTCCACTGTAC 5′-CTGTTCTTCACTCTTGGCTCCT
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performed normalizing to the expression of TBP only
yielding similar results.
Protein expression
Placenta were lysed with a RIPA buffer consisting of
50 mM Tris, 1 % Triton-X, 0.1 % SDS, 0.5 % DOC,
150 mM NaCl, and protease inhibitor cocktail (Roche,
Applied Science, VIC, Australia). Tissue was disrupted
by violent shaking for 2 × 2 minutes at 30 Hz with a
5 mm stainless steel bead in a TissueLyser (Qiagen).
After lysis, the sample was centrifruged for 10 min at 4 °
C and the protein content in the supernatant determined
by bicinchoninic acid assay (Sigma-Aldrich, Castle Hill,
NSW, Australia). 30 μg of protein was loaded onto a 4–
12 % gradient NuPAGE® Bis-Tris gel (Life Technologies,
Mulgrave, VIC, Australia), transferred onto a polyvinyli-
dene difluoride (PVDF) membrane (Millipore, Kilsythe,
VIC, Australia) and blocked for 1 hour with 5 % non-fat
dry milk in PBS-Tween. Primary antibody for rabbit anti-
LPL (1:300, sc-32885 Santa Cruz Biotech, Texas, USA),
rabbit anti-HSL (1:150, sc-25843 Santa Cruz Biotech),
rabbit anti-EL (1:150, 100030 Cayman chemical, Michigan,
USA), or rabbit anti-ATGL (1:300, 2138 Cell Signalling
Technology, Massachusetts, USA were co-incubated with
mouse anti-β-Actin (1:20000, A5316, Sigma Aldrich) over-
night at 4 °C with agitation. Secondary LI-COR antibodies,
goat anti-rabbit 800CW (1:10000, 926–32211, LI-COR)
and donkey anti-mouse 680LT (1:15000, 926–68022, LI-
COR) were incubated for 1 hour at room temperature and
protein was detected by the Odyssey Infrared Imaging Sys-
tem (LI-COR). Lipase protein expression was analyzed by
densitometry correcting for differences in protein loading
by using β-actin levels.
Immunohistochemistry
Paraffin-embedded sections (5 μm) were baked, and
rehydrated. Antigen retrieval was performed by heat-
ing to 125 degrees °C in 100 mM sodium citrate,
0.05 % Tween 20 at pH 6.0 for 30 minutes. Endogen-
ous peroxidase activity was blocked with hydrogen
peroxide 3 % for 10 mins followed by 15 mins with
Biocare Background Sniper (MACH2, Biocare Med-
ical, Concord CA). Immunolabelling was performed
using polyclonal rabbit antibodies to LPL, anti-HSL,
anti-EL antibodies (Biorbyt, Cambridge, UK: LPL
(1:1000, orb13546), EL (1:500, orb100394), HSL
(1:100, orb40070)) and ATGL antibody (1:100, Cell
Signalling Technology). Confirmatory immunohisto-
chemistry for LPL was performed with a second
polyclonal rabbit antibody (1:1000, Santa Cruz Bio-
tech, sc-32885). After washing, the slides were incubated
with a biotinylated polyvalent goat secondary antibody
followed by DAB incubation for 1 minute. Slides were
counterstained with Harris’ Haematoxylin (HHS 16,
Sigma Aldrich) and mounted with coverslips.
Image analysis
HSL protein expression was analyzed with a quantita-
tive immunohistochemistry method described by Helps
et al. [28]. This method uses Ruifrok and Johnston's
color deconvolution image processing method to digit-
ally separate hematoxylin and DAB staining. The im-
aging processing and analysis was performed in NIH-
ImageJ software using Landini’s ImageJ plugin then
histogram analysis and a weighting calculation to esti-
mate the amount of DAB staining. We took 10 ran-
domly selected frames from each of 4 control and 4 PE
placentae that were processed and stained concurrently.
Within each frame, the placental villi were demarcated
by hand on the NIH-ImageJ software.
Lipase activity
Three milligrams of tissue was homogenized in 300 uL
of ice cold assay buffer (150 mM NaCl, 10 mM Tris,
2 mM EDTA, pH 7.4) for 4 mins at 30Hz with a stain-
less steel bead using the Tissue lyser II (Qiagen). Ho-
mogenates were centrifuged for 10 mins at 10000 X g at
4 °C. Lipase enzyme activity was measured in superna-
tants using a commercial kit (Roar Biomedical, New York,
USA) according to the manufacturer’s instructions. LPL
activity in the supernatant was measured in duplicate by a
fluorescence method as described by the assay manufac-
turer. The fluorescence of each sample was normalised to
mg of tissue. Measurements were made at baseline, 30
and 45 mins of incubation, and the result is expressed as
change from baseline.
LPL promoter Methylation
100 ng of genomic DNA was bisulfite treated using the
BisulFlash DNA modification kit (Epigentek, USA). Primers
for bisulfite-converted DNA were designed with the online
tool Methprimer (www.urogene.org//methprimer) covering
4 CpG sites in the LPL promoter region from bp −236
to −46 prior to the transcription start site of the LPL
promoter. Primer sequences: left primer 5′-TGAGGGA
GGATTGTAAGTGATAAATA, right primer 5′- CCCT
ATCTAAACACCAAACACAAAT. 20 ng bisulfite-treated
DNA was PCR amplified with 1 cycle at 95 °C for
10 min, 40 cycles of 95 °C for 30 sec, 55 °C for 40 sec
and 72 °C for 60 sec, followed by 1 cycle of 7 min at
72 °C. The PCR products were then supplied to a se-
quencing facility (AGRF, St Lucia QLD Australia) for
capillary sequencing. Sequencing results were analysed
with the online software tool for bisulfite-treated DNA
BiQ (biq-analyzer.bioinf.mpi-inf.mpg.de/) giving the
proportion of methylated and unmethylated residues
at each CpG site.
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Statistical analysis
Experiments were performed in duplicate. Data are pre-
sented as mean +/− SEM unless stated otherwise. Differ-
ences between groups were examined with two tailed
Mann–Whitney U tests (Prism version 5.03 software
(GraphPad, La Jolla, CA)). Significance was set at < 0.05.
Correlation analysis was performed with Spearman’s rho
testing. Sensitivity analyses were performed excluding
the data from the women with SGA infants and no dif-
ference was seen from the presented results.
Results
Study participants
Placentae from 16 women with preeclampsia (PE) and
20 normotensive (control) women were collected. This
study includes women with late onset rather than early
onset (pre 32 weeks gestation) PE. The women were
matched for maternal BMI and gestational age of deliv-
ery. Maternal and pregnancy characteristics are shown
in Table 2. There were 4 infants (25 %) born to women
with PE who were small for gestational age infants
(SGA). The mean gestational age of delivery did not dif-
fer between groups. The earliest delivery in women with
PE was at 35.1 weeks and in the control group was
36.6 weeks.
ATGL
ATGL was localized to syncytiotrophoblasts, endothelial
cells and stromal cells including Hofbauer cells and
decidual cells (Fig. 1a, b). The relative expression of
ATGL mRNA was reduced in placenta from women
with PE (PE median 0.15 AU (IQR 0.08–0.32) vs control
(1.08 AU (0.30–1.57), P = 0.0003) (Fig. 1c). As the PE
group included 4 women with SGA infants, we have also
shown the PE alone and SGA alone results for mRNA
expression in Fig. 1c. Given the smaller numbers, we did
not perform statistical analyses on these different groups.
There was no clear difference in the protein expression
between placentae from control women or those with PE
for ATGL (PE median 0.84 AU (IQR 0.52–1.20) vs control
(0.77 AU (0.55–1.61), P = 0.98) (Fig. 1d, e).
HSL
HSL was localized to syncytiotrophoblasts and endothe-
lial cells but also to stromal cells including Hofbauer
cells and decidual cells (Fig. 2a, b). The relative expres-
sion of HSL mRNA was reduced in placenta from
women with PE (PE median 0.11 AU (IQR 0.06–0.15) vs
control (0.83 AU (0.30–1.66), P < 0.0001) (Fig. 2c). HSL
protein expression was assessed by quantitative immu-
nohistochemistry. There was a reduction in HSL protein
expression in placentae from women with PE compared
to control (PE median 42.0 %DAB staining (IQR 36.5–
48.7), Control 45.0 %DAB staining (39.7–53.6), P <
0.0001) (Fig. 2d).
LPL and EL
The extracellular lipases LPL (Fig. 3a, b) and EL (Fig. 4a, b)
were localized to syncytiotrophoblasts, endothelial cells and
also to stromal cells including Hofbauer cells and decidual
cells. The relative expression of LPL and EL mRNA were
reduced in the placenta from women with late onset PE
((LPL: PE median 0.13 AU (IQR 0.08–0.33) vs control
(0.57 AU (0.26–0.98), P < 0.0001) and EL: PE median
0.03 AU (IQR 0.01–0.09) vs control (0.68 AU (0.41–1.67),
P < 0.0001)). There was no clear difference in the protein
expression between placentae from control women or those
with PE for LPL (PE median 0.63 AU (IQR 0.47–1.16) vs
control (0.95 AU (0.61–1.33), P = 0.19) (Fig. 3e, f) or EL
(PE median 0.68 AU (IQR 0.31–1.81) vs control (0.57 AU
(0.30–0.74), P = 0.48) (Fig. 4d, e). DNA methylation of 4
CpG sites in the LPL promoter was investigated by bisulfite
sequencing. While the levels of methylation varied between
the CpG sites, there was no difference in the proportion of
methylated vs unmethylated CpG sites in the LPL promoter
between PE and control placentae (Fig. 3g).
Lipase activity
Lipase activity was measured as fluorescence emission of
hydrolyzed substrate in response to lipase enzyme activ-
ity and was tested in homogenized placental tissue
samples. Lipase activity was measured at 30 and 45 mi-
nutes at room temperature (Fig. 5). There was no
difference in placental lipase activity between PE and
control pregnancies at 30 (PE median 0.39 (IQR 0.36–
0.66) vs. control 0.32 (IQR 0.28–0.57), P = 0.12) or 45 mi-
nutes (PE median 0.65 (IQR 0.51–1.09) vs. control 0.53
(0.47–0.96), P = 0.35).
Relationship with clinical factors
There was no relationship between the mRNA expres-
sion of any lipase and maternal early pregnancy BMI or
infant birth weight for women with or without PE.
Table 2 Clinical characteristics
Control PE P
n 20 16
Maternal age (years) 32.6 (1.0) 31.0 (1.6) 0.40
Maternal BMI in early pregnancy
(mean(SD))
26.9 (1.5) 27.6 (1.6) 0.90
Caucasian ethnicity n (%) 19 (95) 16 (100) 1.0
Gestational age of delivery (weeks) 38.7 (0.2) 38.2 (0.4) 0.26
Birth weight (g) 3442 (86.84) 3056 (142.5) 0.06
Birth weight centilea 55.3 (7.2) 38.55 (7.60) 0.15
SGA n(%) b 0 4 (25) 0.03
Infant sex (F/M) 9/11 8/9 1.0
aAdjusted birthweight centile [33] badjusted birth centile <10th
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Discussion
The current study, examining placentae from women with
late onset PE and BMI matched women with uncomplicated
pregnancies, has demonstrated reduced mRNA expression
and reduced protein expression of HSL in placentae from
women with PE. ATGL, LPL and EL showed reduced
mRNA expression but unchanged protein expression. All
lipases examined localized to the maternal and fetal sides of
the placenta as well as the Hofbauer cells and decidual cells.
There was no difference in localization between PE and
control placentae for any of the four lipases described in this
study, but we have demonstrated they are present in
placental cells expected to be metabolically active.
The strengths of this study include a well character-
ized and matched cohort, however there are some limi-
tations. For example, the HSL protein expression data in
the current study needs to be assessed with some cau-
tion. We were unable to obtain western blot results for
HSL, suggesting low levels of protein expression of HSL.
Human HSL protein concentrations are high in adipo-
cytes but much lower in other tissues such as skeletal
muscle [29]. HSL mRNA is clearly present in placenta
and HSL was localised with selective antibody by immu-
nohistochemistry. Quantification of protein expression
by image analysis is a validated technique, however, as
with any analysis, it is possible that the reported reduc-
tion in HSL is a result of a type 1 error.
In late onset PE the fetus is usually well grown. The
presence of a growth restricted fetus suggests that the
PE is more severe or that another pathology underlies
the growth restriction [30]. The inclusion of placentae
from women with growth restricted infants in our study
is therefore a potential confounder. However, we per-
formed sensitivity analyses which did not change the dir-
ection or significance of any results indicating that the
presence or absence of placentae related to growth re-
stricted infants did not influence the results. Our sam-
ples were obtained from women with late onset PE only,
which could have implications for applying our results
to general PE. Early PE has been postulated to have
quite different placental pathology and function to late
PE [31, 30]. The findings of this study should therefore
not be extrapolated to early PE, and the potential differ-
ences due to gestational age should be considered.
Fig. 1 ATGL. a Immunohistochemisty for the detection of ATGL in control placenta, open arrow indicates endothelial cell staining, closed arrow
indicates trophoblast staining. b immunohistochemistry in PE placenta, bar indicating 50 um. c negative control. d ATGL mRNA expression of
control, all PE, PE alone and PE/SGA cases. e Representative Western blot result. f Relative protein expression of ATGL in control and PE placentae,
boxes represent median with interquartile range, whiskers indicating 2.5–97.5 %, *, P < 0.05
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ATGL and HSL have not previously been examined in
placentae from women with PE. We have recently shown
that ATGL mRNA was increased and HSL mRNA de-
creased, with no difference in protein expression, in obese
women with well controlled gestational diabetes mellitus
compared to BMI matched controls [32]. ATGL and HSL
are both intracellular lipases. They are involved in the
mobilization of triacylglycerol from lipid droplets with
ATGL mainly converting triacylglycerol to diacylglycerol
and HSL converting diacylglycerol to monoacylglycerol.
The decrease in ATGL and HSL mRNA and HSL protein
seen here could result in reduced lipolysis of placental lipid
droplets and hence reduced lipid transfer to the fetus.
In the current study, LPL mRNA expression was re-
duced in placentae from women with PE. However, there
was no difference in protein expression or localisation.
LPL mRNA expression has previously been found to be
unchanged in PE [21] and unchanged [21] or increased
in growth restricted infants [19, 20]. One reason for the
disparity between our findings and the earlier studies with
respect to growth restricted infants is the gestational age
at delivery. In both the studies showing a reduced LPL
mRNA expression in placentae from pregnancies with
growth restricted infants, the placentae were from preg-
nancies delivered at a mean gestational age of 32 weeks at
delivery, whereas delivery was at 39 weeks in the Laivouri
study [21]. The mean gestational age at delivery of the pla-
centae in our study is 38 weeks and the lack of change
seen is consistent with the lack of change seen at the later
gestation in the Laivouri study. The difference in gesta-
tional age rather than the condition itself could underlie
the increase in LPL mRNA seen in the studies comparing
32 week placenta to term placenta.
EL mRNA expression was also reduced in placentae
from women with PE, with no change in protein expres-
sion or localisation. EL expression has been previously
found to be decreased in growth restricted infant associ-
ated placaentae compared with control [19]. It needs to
be noted that this finding was in a cohort comparing
term control and 32 week growth restricted infant re-
lated placentae, and that they reported an increase in
placental EL expression from the first to third trimester.
Once again, in our study, with careful matching of gesta-
tional age, EL protein expression was unchanged in PE.
The current study found no difference in overall lipase
activity measured in placental biopsies. This is consistent
with the results of a previous study in preterm and term
pregnancies complicated by growth restricted infants
that reported no change in overall placental triglyceride
hydrolase activity but reduced LPL activity in isolated
Fig. 2 HSL. a Immunohistochemisty for the detection of HSL in control placenta, open arrow indicates endothelial cell staining, closed arrow
indicates trophoblast staining. b immunohistochemistry in PE placenta. c negative control. d mRNA expression, showing control compared with
all PE cases with the result of statistical analysis, as well as the result for PE alone or PE/SGA cases. e Relative protein expression as measured by
semi-quantitative immunohistochemistry. *, P < 0.05
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Fig. 3 LPL. a Immunohistochemisty for the detection of LPL in control placenta, open arrow indicates endothelial cell staining, closed arrow
indicates trophoblast staining. b immunohistochemistry in PE placenta. c negative control. d mRNA expression, showing control compared with
all PE cases with the result of statistical analysis, as well as the result for PE alone or PE/SGA cases. e Representative Western blot result. f Relative
protein expression, boxes represent median with interquartile range, whiskers indicating 2.5–97.5 %, *, P < 0.05. g LPL methylation analysis
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placental microvillous membrane [18]. In contrast, an
older study showed greater LPL but lower intracellular
lipase activity in placentae from PE and IUGR pregnancy
[22]. The assay used in the current study is conducted at
pH 7 and measures overall triglyceride hydrolase activity.
The similar lipase activity levels we report are in keeping
with the lack of change in protein levels for 3 of 4 lipases
we examined, suggesting that in term PE, placental li-
pases are unaltered.
Conclusion
The current study demonstrated a decrease in mRNA
expression in all four lipases. A small decrease in HSL
protein was seen, but no changes in protein expression
for ATGL, LPL or EL were demonstrated. There was no
difference in lipase activity in placentae from pregnan-
cies complicated by late onset PE compared to control.
This suggests that this aspect of placental lipid process-
ing is not altered in late onset PE and does not underlie
the differences seen in infant growth.
Fig. 4 EL. a Immunohistochemisty for the detection of EL in control placenta, b immunohistochemistry in PE placenta, open arrow indicates
endothelial cell staining, closed arrow indicates trophoblast staining. . c negative control. d mRNA expression, showing control compared with
all PE cases with the result of statistical analysis, as well as the result for PE alone or PE/SGA cases. e Representative Western blot result, boxes
represent median with interquartile range, whiskers indicating 2.5–97.5 %, *, P < 0.05. f Relative protein expression
Fig. 5 Lipase activity. Change in placental lipase activity taken at 30
and 45 mins, intissue from control pregnancies in white, and PE in
grey. n = 8 control and n = 14 PE. Corrected to mg of tissue
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